CMS call letter for Medicare Advantage with a focus on rate setting and risk adjustment
CMS regulations related to the treatment of Medicare Part C and Part D
CMS regulations pertaining to reimbursement rates for ESRD-related services.
H.R. 2 the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (All provisions)
S. 598 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 (All provisions)
H.R. 1130 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 (All provisions)
Education on issues related to veterans dialysis services.
Duration: February 24, 2012
to
March 31, 2015
General Issues: Health Issues , Medicare/Medicaid , Veterans , Insurance
Spending: about $780,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2012: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Sarah Hamlett Leg Dir, Rep. Thelma Drake; Leg Asst, Rep. Ed Schrock
Legislative Director, Rep. Drake
Legislative Asst, Rep. Ed Schrock
Meghan Johnson Chief of Staff, Rep. Linda Sanchez
Sarah ha Legislative Asst, Rep. Ed Schrock
Robert Collins Deputy Chief of Staff, Office of the Minority Whip
Chief of Staff, Rep. Cantor; Press Secretary, Sen. Hagel
Staff Assistant, Rep Riggs
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2015
Purple Advocacy, LLC terminated an engagement in which they represented DaVita Inc. on April 22, 2015.
Original Filing: 300728585.xml
Lobbying Issues
CMS call letter for Medicare Advantage with a focus on rate setting and risk adjustment
CMS regulations related to the treatment of Medicare Part C and Part D
CMS regulations pertaining to reimbursement rates for ESRD-related services.
H.R. 2 the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (All provisions)
S. 598 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 (All provisions)
H.R. 1130 Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 (All provisions)
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
Lobbying Issues
Education on issues related to veterans dialysis services.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Purple Advocacy, LLC lobbied for DaVita Inc. , earning $60,000. The report was filed on Jan. 21, 2015.
Original Filing: 300708982.xml
Lobbying Issues
End-stage renal disease reimbursement and policies related to the Medicare End Stage Renal Disease Prospective Payment System; and issues related to state-based health insurance exchanges and patient protections for patients under the Affordable Care Act (Public Law 112-25).
HR 4814 The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014.
CMS regulations related to the treatment of Medicare Part C and D.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
Lobbying Issues
Legislative provisions related to veteran dialysis facilities
Agencies Lobbied
U.S. Senate
3rd Quarter, 2014
In Q3, Purple Advocacy, LLC lobbied for DaVita Inc. , earning $60,000. The report was filed on Oct. 22, 2014.
Original Filing: 300689720.xml
Lobbying Issues
End-stage renal disease reimbursement and policies related to the Medicare End Stage Renal Disease Prospective Payment System; and issues related to state-based health insurance exchanges and patient protections for patients under the Affordable Care Act (Public Law 112-25).
HR 4814 The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014.
CMS regulations related to the treatment of Medicare Part C and D.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 4486: Military Construction and Veterans Affairs, and Related Agencies Appropriations Act, 2015 - Provisions related to veteran dialysis facilities
H.R. 3831: Veterans Dialysis Pilot Program Review Act of 2014
S. 1547: Veterans Dialysis Pilot Program Review Act of 2013
Agencies Lobbied
U.S. Senate
2nd Quarter, 2014
In Q2, Purple Advocacy, LLC lobbied for DaVita Inc. , earning $60,000. The report was filed on July 21, 2014.
Original Filing: 300668214.xml
Lobbying Issues
End-stage renal disease reimbursement and policies related to the Medicare End Stage Renal Disease Prospective Payment System; and issues related to state-based health insurance exchanges and patient protections for patients under the Affordable Care Act (Public Law 112-25).
Final Regulations issued by CMS regading Medicare payments for services for people living with ESRD.
H.R. 4302- Protecting Access to Medicare Act of 2014 and provisions related to the treatment of bundled payments for ESRD providers participating in Medicare.
HR 4814 The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014.
Agencies Lobbied
U.S. Senate
Lobbying Issues
End-stage renal disease reimbursement and policies related to the Medicare End Stage Renal Disease Prospective Payment System; and issues related to state-based health insurance exchanges and patient protections for patients under the Affordable Care Act (Public Law 112-25).
Final Regulations issued by CMS regading Medicare payments for services for people living with ESRD.
H.R. 4302- Protecting Access to Medicare Act of 2014 and provisions related to the treatment of bundled payments for ESRD providers participating in Medicare.
HR 4814 The Chronic Kidney Disease Improvement in Research and Treatment Act of 2014.
S. 2501 Hospital Readmissions Program Accuracy and Accountability Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Education related to veterans' access to outpatient dialysis.
Agencies Lobbied
U.S. Senate
1st Quarter, 2014
In Q1, Purple Advocacy, LLC lobbied for DaVita Inc. , earning $60,000. The report was filed on April 21, 2014.
Original Filing: 300649008.xml
Lobbying Issues
End-stage renal disease reimbursement and policies related to the Medicare End Stage Renal Disease Prospective Payment System; and issues related to state-based health insurance exchanges and patient protections for patients under the Affordable Care Act (Public Law 112-25).
Final Regulations issued by CMS regading Medicare payments for services for people living with ESRD.
H.R. 4302- Protecting Access to Medicare Act of 2014 and provisions related to the treatment of bundled payments for ESRD providers participating in Medicare.
Agencies Lobbied
U.S. Senate
4th Quarter, 2013
In Q4, Purple Advocacy, LLC lobbied for DaVita Inc. , earning $60,000. The report was filed on Jan. 22, 2014.
Original Filing: 300627305.xml
Lobbying Issues
End-stage renal disease reimbursement and policies related to the Medicare End Stage Renal Disease Prospective Payment System; the Affordable Care Act (Public Law 112-25); H.R. 8 - The American Taxpayer Relief Act of 2012, and subsequent rule making; S. Con. Res. 8 - Senate Budget Resolution for FY 2014; and H.J. Res 59 - Continuing Appropriations Resolution for 2014.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
3rd Quarter, 2013
In Q3, Purple Advocacy, LLC lobbied for DaVita Inc. , earning $60,000. The report was filed on Oct. 22, 2013.
Original Filing: 300608113.xml
Lobbying Issues
End-stage renal disease reimbursement and policies related to the Medicare End Stage Renal Disease Prospective Payment System; the Affordable Care Act (Public Law 112-25); H.R. 8 - The American Taxpayer Relief Act of 2012, and subsequent rule making.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
2nd Quarter, 2013
In Q2, Purple Advocacy, LLC lobbied for DaVita Inc. , earning $60,000. The report was filed on July 22, 2013.
Original Filing: 300585352.xml
Lobbying Issues
End-stage renal disease reimbursement and policies related to the Medicare End Stage Renal Disease Prospective Payment System; the Affordable Care Act (Public Law 112-25); H.R. 8 - The American Taxpayer Relief Act of 2012, and subsequent rule making.
Agencies Lobbied
U.S. Senate
Type of Issue
Medicare/Medicaid
1st Quarter, 2013
In Q1, Purple Advocacy, LLC lobbied for DaVita Inc. , earning $60,000. The report was filed on April 22, 2013.
Original Filing: 300561194.xml
Lobbying Issues
End-stage renal disease reimbursement and policies related to the Medicare End Stage Renal Disease Prospective Payment System, the Affordable Care Act (Public Law 112-25), and H.R. 8 - The American Taxpayer Relief Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
End-stage renal disease reimbursement and policies related to the Medicare End Stage Renal Disease Prospective Payment System, the Affordable Care Act (Public Law 112-25), and H.R. 8 - The American Taxpayer Relief Act of 2012.
Agencies Lobbied
U.S. Senate
4th Quarter, 2012
In Q4, Purple Advocacy, LLC lobbied for DaVita Inc. , earning $60,000. The report was filed on Jan. 22, 2013.
Original Filing: 300541494.xml
Lobbying Issues
End-stage renal disease reimbursement and policies related to the new End Stage Renal Disease Prospective Payment System; and the new health care law (Public Law 112-25).
H.R. 8 - American Taxpayer Relief Act of 2012, specifically Medicare related offsets and impact to the ESRD bundled payment system.
Agencies Lobbied
U.S. Senate
Type of Issue
Medicare/Medicaid
3rd Quarter, 2012
In Q3, Purple Advocacy, LLC lobbied for DaVita Inc. , earning $60,000. The report was filed on Oct. 19, 2012.
Original Filing: 300513556.xml
Lobbying Issues
Medicare end-stage renal disease reimbursement and policies related to the new Healthcare Exchange; Medicare reimbursement of ESRD related drugs
Agencies Lobbied
U.S. Senate
Type of Issue
Medicare/Medicaid
2nd Quarter, 2012
In Q2, Purple Advocacy, LLC lobbied for DaVita Inc. , earning $60,000. The report was filed on July 19, 2012.
Original Filing: 300492984.xml
Lobbying Issues
Medicare end-stage renal disease reimbursement and policies related to Medicare Secondary Payor and subsidy provisions in the new Healthcare Exchange
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare end-stage renal disease reimbursement and policies related to Medicare Secondary Payor and subsidy provisions in the new Healthcare Exchange.
Agencies Lobbied
U.S. Senate
Type of Issue
Medicare/Medicaid
Lobbying Issues
Issues related to Veterans on dialysis care.
Agencies Lobbied
U.S. Senate
1st Quarter, 2012
In Q1, Purple Advocacy, LLC lobbied for DaVita Inc. , earning $60,000. The report was filed on April 13, 2012.
Original Filing: 300460337.xml
Lobbying Issues
End-stage renal disease reimbursement and policies related to Medicare Secondary Payor provisions in the new Healthcare Exchange.
Agencies Lobbied
U.S. Senate
Type of Issue
Medicare/Medicaid
1st Quarter, 2012
Purple Advocacy, LLC filed a lobbying registration on Feb. 24, 2012 to represent DaVita Inc., effective Feb. 24, 2012.
Original Filing: 300456165.xml
Issue(s) they said they’d lobby about: Issues related to end-stage renal disease reimbursement and policies under the Medicare End-Stage Renal Disease Prospective Payment System and the new healthcare exchanges (Public Law 112-25). .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...